Alosetron HCl
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317171

CAS#: 122852-69-1 (HCl)

Description: Alosetron is a potent and selective 5-HT3 receptor antagonist. Alosetron blocks the actions of serotonin at 5-HT3 sites in the peripheral nervous system, particularly on enteric and nociceptive sensory neurons, thereby affecting the regulation of visceral pain, decreasing gastrointestinal contraction and motility, and decreasing gastrointestinal secretions. This agent is used to treat diarrhea-predominant irritable bowel syndrome in women only.


Chemical Structure

img
Alosetron HCl
CAS# 122852-69-1 (HCl)

Theoretical Analysis

MedKoo Cat#: 317171
Name: Alosetron HCl
CAS#: 122852-69-1 (HCl)
Chemical Formula: C17H19ClN4O
Exact Mass: 294.15
Molecular Weight: 330.816
Elemental Analysis: C, 61.72; H, 5.79; Cl, 10.72; N, 16.94; O, 4.84

Price and Availability

Size Price Availability Quantity
100mg USD 285 2 Weeks
250mg USD 550 2 Weeks
Bulk inquiry

Related CAS #: 122852-42-0 (free base)   122852-69-1 (HCl)    

Synonym: Alosetron HCl; Alosetron hydrochloride; Lotronex; GR68755; GR-68755; GR 68755;

IUPAC/Chemical Name: 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one hydrochloride

InChi Key: FNYQZOVOVDSGJH-UHFFFAOYSA-N

InChi Code: InChI=1S/C17H18N4O.ClH/c1-11-13(19-10-18-11)9-21-8-7-15-16(17(21)22)12-5-3-4-6-14(12)20(15)2;/h3-6,10H,7-9H2,1-2H3,(H,18,19);1H

SMILES Code: O=C1N(CC2=C(C)NC=N2)CCC(N3C)=C1C4=C3C=CC=C4.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 330.82 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Alosetron. 2019 Feb 7. PMID: 30222295.


2: Balfour JA, Goa KL, Perry CM. Alosetron. Drugs. 2000 Mar;59(3):511-8; discussion 519-20. doi: 10.2165/00003495-200059030-00008. PMID: 10776833.


3: Butt I, Kasmin F. Alosetron. 2022 Dec 5. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 31971721.


4: Mucke H, Cole P, Rabasseda X. Alosetron. Drugs Today (Barc). 2000 Sep;36(9):595-607. doi: 10.1358/dot.2000.36.9.593776. PMID: 12847565.


5: Mayer EA, Bradesi S. Alosetron and irritable bowel syndrome. Expert Opin Pharmacother. 2003 Nov;4(11):2089-98. doi: 10.1517/14656566.4.11.2089. PMID: 14596662.


6: Bleser S. Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes. Curr Med Res Opin. 2011 Mar;27(3):503-12. doi: 10.1185/03007995.2010.547933. Epub 2011 Jan 6. PMID: 21208139.


7: Lembo A, Sultan S, Chang L, Heidelbaugh JJ, Smalley W, Verne GN. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea. Gastroenterology. 2022 Jul;163(1):137-151. doi: 10.1053/j.gastro.2022.04.017. PMID: 35738725.


8: Camilleri M. Pharmacology and clinical experience with alosetron. Expert Opin Investig Drugs. 2000 Jan;9(1):147-59. doi: 10.1517/13543784.9.1.147. PMID: 11060667.


9: Savarino E, Zingone F, Barberio B, Marasco G, Akyuz F, Akpinar H, Barboi O, Bodini G, Bor S, Chiarioni G, Cristian G, Corsetti M, Di Sabatino A, Dimitriu AM, Drug V, Dumitrascu DL, Ford AC, Hauser G, Nakov R, Patel N, Pohl D, Sfarti C, Serra J, Simrén M, Suciu A, Tack J, Toruner M, Walters J, Cremon C, Barbara G. Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility. United European Gastroenterol J. 2022 Jul;10(6):556-584. doi: 10.1002/ueg2.12259. Epub 2022 Jun 13. PMID: 35695704; PMCID: PMC9278595.


10: Hyman PE, Garvey TQ 3rd. Return of alosetron. Expert Opin Drug Saf. 2002 May;1(1):1-4. doi: 10.1517/14740338.1.1.1. PMID: 12904154.


11: Gunput MD. Review article: clinical pharmacology of alosetron. Aliment Pharmacol Ther. 1999 May;13 Suppl 2:70-6. doi: 10.1046/j.1365-2036.1999.00009.x. PMID: 10429744.


12: Black CJ, Ford AC. Best management of irritable bowel syndrome. Frontline Gastroenterol. 2020 May 28;12(4):303-315. doi: 10.1136/flgastro-2019-101298. PMID: 34249316; PMCID: PMC8231425.


13: Lembo A, Weber HC, Farraye FA. Alosetron in irritable bowel syndrome: strategies for its use in a common gastrointestinal disorder. Drugs. 2003;63(18):1895-905. doi: 10.2165/00003495-200363180-00002. PMID: 12930162.


14: Moynihan R. Alosetron: a case study in regulatory capture, or a victory for patients' rights? BMJ. 2002 Sep 14;325(7364):592-5. doi: 10.1136/bmj.325.7364.592. PMID: 12228140; PMCID: PMC1124108.


15: Andresen V, Hollerbach S. Reassessing the benefits and risks of alosetron: what is its place in the treatment of irritable bowel syndrome? Drug Saf. 2004;27(5):283-92. doi: 10.2165/00002018-200427050-00001. PMID: 15061683.


16: Linezolid, Alosetron, Levetiracetam. Am J Health Syst Pharm. 2000 Aug 15;57(16):1480-4. PMID: 10965393.


17: Gallo-Torres H, Brinker A, Avigan M. Alosetron: ischemic colitis and serious complications of constipation. Am J Gastroenterol. 2006 May;101(5):1080-3. doi: 10.1111/j.1572-0241.2006.00650.x. PMID: 16696787.


18: Chang L, Chey WD, Harris L, Olden K, Surawicz C, Schoenfeld P. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol. 2006 May;101(5):1069-79. doi: 10.1111/j.1572-0241.2006.00459.x. PMID: 16606352.


19: Audolfsson G, Bayguinov O, Yamamoto T, Somogyi GT, Schraut WH, Sanders KM, Bauer AJ. Review article: effects of the 5-HT3 receptor antagonist alosetron on neuromuscular transmission in canine and human intestinal muscle. Aliment Pharmacol Ther. 1999 May;13 Suppl 2:39-47. PMID: 10429739.


20: Lièvre M. Alosetron for irritable bowel syndrome. BMJ. 2002 Sep 14;325(7364):555-6. doi: 10.1136/bmj.325.7364.555. PMID: 12228116; PMCID: PMC1124090.